BOSTON, March 27, 2017 /PRNewswire/ --BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that the company's Interrogative Biology® Platform contributed to the discovery of new data using a cold-induced model to promote thermogenesis and facilitate brown fat metabolism. Joslin Diabetes Center led the investigation with BERG providing its Interrogative Biology® platform for analysis of samples. The findings were published in Nature Medicine(DOI number: 10.1038/nm.4297) onMarch 27, 2017.
Researchers at Joslin state in an announcement on the findings that, activated by cold, small amounts of brown fat in the body can burn calories to warm up a person. Brown fat can also help to lower insulin resistance and other conditions implicated in type 2 diabetes and obesity. Since the discovery in 2009 that brown fat can be active in adult humans, researchers around the world have worked to unveil ways to switch on this fat. Scientists at Joslin, guided by BERG's advanced lipidsanalysis, now have identified a new route to throw the switch.
The investigators have shown that a lipid (a fat-like substance) called 12,13-diHOME molecules that circulates in the blood signals brown fat cells in mice to fuel up with other lipids. In one experiment, obese mice given low levels of the molecule produced reduced levels of blood triglycerides-other forms of lipids that can increase risks for heart disease and diabetes in humans. Although the Joslin team hasn't shown that 12,13-diHOME also triggers brown fat activation in humans, the lipid could aid research by acting as a biomarker for the process, notes Yu-Hua Tseng, Ph.D., a Joslin principal investigator and senior author on the paper.
The researchers are now gathering more details on the molecular mechanisms by which 12,13-diHOME may affect brown fat activation. If the lipid does indeed assist in activating brown fat in humans, it may offer a route toward therapies, and the route may attract particular interest because we produce this substance naturally. "We would like to take our research from the bench to the bedside by engaging with clinical investigators here at Joslin," Tseng says.
The study began with a cohort of nine healthy human volunteers, taking blood samples first at normal room temperatures and then at temperatures cold enough to activate brown fat. Levels of 12,13-diHOME rose significantly among all the volunteers in the cold. Additionally, knowing that brown fat activity in humans decreases as obesity increases, the team measured circulating 12,13-diHOME in 55 people with a wide range of ages and body weights. The scientists found a negative correlation of 12,13-diHOME with measures of body mass index (BMI), insulin resistance, circulating triglycerides and liver enzymes that are related to fatty liver disease. In mice models, studies similarly showed that this lipid can activate fuel uptake into brown fat, and improve brown fat performance.
"This paper represents a novel method for studying metabolic diseases by introducing an environmental element, in this case cold exposure, to activate brown fat and potentially advanceinnovative treatments in diabetes," saidNiven R. Narain, BERG Co-Founder, President and Chief Executive Officer of BERG. "We are very pleased to be a part of this important study with Joslin Diabetes Center and are encouraged by these new findings. Through our Interrogative Biology® platform, we hope to able to identify important biomarkers for future studies that can speed the delivery of meaningful treatments to patients."
About BERG
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles, demographics and biology. BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic product candidates and develop companion diagnostics to enhance specificity in its drug development process. BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology.
For additional information, please visitwww.BERGhealth.com.
CONTACT:
Lisa Rivero
Ogilvy
+1.617.761.6746
